Silibinin induces apoptosis and inhibits proliferation of estrogen receptor (ER)-negative breast carcinoma cells through suppression of nuclear factor kappa B activation

Archives of Iranian Medicine

Volumn 17, Issue 5, 2014, Pages 366-371

  Yousefi, Meysam ^a   Ghaffari, Seyed H ^a   Zekri, Ali ^a   Hassani, Saeed ^a   Alimoghaddam, Kamran ^a   Ghavamzadeh, Ardeshir ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Estrogen receptor; NF B; Silibinin

Indexed keywords

ESTROGEN RECEPTOR; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SILIBININ; ANTINEOPLASTIC AGENT; DNA; SILYMARIN;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRDU ASSAY; BREAST CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; METABOLIC ACTIVITY ASSAY; MTT ASSAY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NF-KAPPA B; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; SILYMARIN;

EID: 84899881654     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer. 2001; 94: 153-156.
2. Warren R. Screening women at high risk of breast cancer on the basis of evidence. European Journal of Radiology. 2001; 39: 50-59.
3. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma J Cell Physiol. 2000; 182: 150-162.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2001; 2: 127-137.
5. Eroles P, Bosch A, Alejandro Pérez-Fidalgo J, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer treatment reviews. 2012; 38: 698-707.
6. Chen X, Levkowitz G, Tzahar E, Karunagaran D, Lavi S, Ben-Baruch N, et al. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem 1996; 271: 7620-7629.
7. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997; 16: 1647-1655.
8. Bardou V-J, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases. Journal of Clinical Oncology. 2003; 21: 1973-1979.
9. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002; 2: 101-112.
10. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers usinimmunohistochemistry. Breast (Edinburgh, Scotland). 2012; 21: 50 57.
11. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009; 8: 33-40.
12. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A. 2000; 97: 8542-8547.
13. Biswas DK, Martin KJ, McAlister C, Cruz AP, Graner E, Dai SC, et al. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation. Cancer Res. 2003; 63: 290-295.
14. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A. 2004; 101: 10137-10142.
15. Biswas DK Dai SC, Cruz A, Weiser B, Graner E, Pardee AB. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers Proc Natl Acad Sci U S A. 2001; 98: 10386-10391.
16. Momeny M, Khorramizadeh MR, Ghaffari SH, Yousefi M, Yekanine-jad MS, Esmaeili R et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phos-phorylation. European Journal of Pharmacology. 2008; 591: 13-20.
17. Singh RP, Agarwal R. Prostate cancer prevention by silibinin Curr Cancer Drug Targets. 2004; 4: 1-11.
18. Son YG, Kim EH, Kim JY, Kim SU, Kwon TK Yoon AR, et al. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res. 2007; 67: 8274-8284.
19. Cheung CW, Taylor PJ, Kirkpatrick CMJ, Vesey DA, Gobe GC, Winterford C, et al. Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels. BJU International. 2007; 100: 438-444.
20. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 2004; 25: 1711-1720.
21. Yang SH, Lin JK Chen WS, Chiu JH. Antiangiogenic effect of silymarin on colon cancer LoVo cell line. J Surg Res. 2003; 113: 133-138.
22. Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog 2004; 40: 143-149.
23. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst. 1997; 89: 556-566.
24. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA Crighton F, Harrison GS, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients Invest New Drugs. 2007; 25: 139-146.
25. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010; 29: 447-463.
26. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene. 2002; 21: 1759-1767.
27. Saliou C, Rihn B, Cillard J, Okamoto T, Packer L. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silBmarin in HepG2. Evidence for different activating pathways. FES Lett. 1998; 440: 8-12.
28. Momeny M, Malehmir M, Zakidizaji M, Ghasemi R, Ghadimi H, Shokrgozar MA et al. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloprotein-ase 9. Anticancer Drugs. 2010; 21: 252-260.
29. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
30. Ahmed A. Prognostic and therapeutic role of nuclear factor-kappa B (NF-kappaB) in breast cancer. Journal of Ayub Medical College, Ab-bottabad: JAMC. 2010; 22: 218-221.
31. Wang HJ, Tashiro S, Onodera S, Ikejima T. Inhibition of insulin-like growth factor 1 receptor signaling enhanced silibinin-induced activation of death receptor and mitochondrial apoptotic pathways in human breast cancer MCF-7 cells. J Pharmacol Sci. 2008; 107: 260-269.
32. Tiwari P, Kumar A, Balakrishnan S, Kushwaha HS, Mishra KP. Silibinin-induced apoptosis in MCF7 and T47D human breast carcinoma cells involves caspase-8 activation and mitochondrial pathway. Cancer Invest. 2011; 29: 12-20.
33. Yousefi M, Ghaffari SH, Soltani BM, Nafissi S, Momeny M, Zekri A, et al. Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-kappaB expressions may play an important role in silibinin-induced response. Neurochem Res. 2012; 37: 2053-2063.
34. Cardone RA Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer. 2005; 5: 786-795.
35. Dizaji M, Malehmir M, Ghavamzadeh A, Alimoghaddam K, Ghaffari S. Synergistic Effects of Arsenic Trioxide and Silibinin on Apoptosis and Invasion in Human Glioblastoma U87MG Cell Line. Neurochem-ical Research. 2012; 37: 370-380.
36. Karin M, Lin A. NF-[kappa]B at the crossroads of life and death Nat Immunol. 2002; 3: 221-227.
37. Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N Inoue J-I. NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nature Communications. 2013; 4: 2299. doi: 10.1038/ncomms3299.
38. Duru N, Candas D, Jiang G, Li J. Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society. J Cancer Res Clin Oncol. 2013; 1-14.
39. Rajkovic-Molek K, Mustac E, Hadzisejdic I, Jonjic N. The Prognostic Importance of Nuclear Factor [kappaB and Hypoxia-inducible Factor 1[alpha] in Relation to the Breast Cancer Subtype and the Overall Survival. Applied Immunohistochemistry & Molecular Morphology. 9000; Publish Ahead of Print: 10.1097/PAI.0b013e31829271ce.
40. Shapochka DO, Zaletok SP, Gnidyuk MI. Relationship between NF-kappaB, ER PR, Her2/neu, Ki67, p53 expression in human breast cancer. Exp Oncol. 2012; 34: 358-363.
41. Pomerantz JL, Baltimore D. TwoPathwaystoNF-κB. Molecular Cell. 2002; 10: 693-695.
42. Derudder E, Dejardin E, Pritchard LL, Green DR Körner M, Baud V. RelB/p50 Dimers Are Differentially Regulated by Tumor Necrosis Factor-a and Lymphotoxin-ß Recetor Activation. Journal of Biological Chemistry. 2003; 278: 23278-23284.